SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): August 16, 2004
ANTARES PHARMA, INC.
(Exact Name of Registrant as Specified in Charter)
Minnesota | 0-20945 | 41-1350192 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
707 Eagleview Boulevard, Suite 414, Exton, PA | 19341 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (610) 458-6200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events
On August 17, 2004, Antares Pharma, Inc. (the Company) issued a press release regarding the appointment of Paul K. Wotton to the Companys Board of Directors. A copy of this press release is furnished as Exhibit 99.1 hereto.
Also on August 17, 2004, the Company issued a press release regarding the resignation of its Chief Executive Officer, Roger G. Harrison, effective as of September 1, 2004. The Company also announced the appointment of Jack Stover to the position of Chief Executive Officer and Director, effective as of September 1, 2004. A copy of this press release is furnished as Exhibit 99.2 hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: August 18, 2004 |
ANTARES PHARMA, INC. | |||
By |
/s/ Lawrence M. Christian | |||
Lawrence M. Christian | ||||
Chief Financial Officer |
EXHIBIT INDEX
99.1 | Press Release issued August 17, 2004 | |
99.2 | Press Release issued August 17, 2004 |